Background
Zhdanava and colleagues conducted a retrospective study to examine how patients with moderate-to-severe plaque psoriasis (PsO) typically use opioids and healthcare resources; these patients were stratified by number of PsO-related comorbidities.1
Methods
Gathering data (dated between January 2010 and March 2017) from a database of privately insured patients, Zhdanava and colleagues identified adults with moderate-to-severe PsO who had 2 or more diagnoses. The date of the first diagnosis was considered the index date. Patients receiving systemic or biologic therapeutics were stratified by the number of PsO-related comorbidities that began within 12 months after the index date. Per-patient-per-year (PPPY) outpatient visits were tracked after the index date until patient eligibility ended or the data were no longer available.1
Patients with less than 12 months coverage before or after the index date or with pre-existing PsO-related comorbidities were not included in the study.1
Results
During the 12 months before the index date, more PsO patients (24.2% of the systemic users and 26.9% of the biologic users) received opioids than non-PsO patients (15.7%). For PsO patients, during the pre-index period, a greater number of comorbidities was associated with increased opioid use. Of systemic users with 0 comorbidities, 21.3% used opioids; with 1 to 2 comorbidities, 27.8%; and with 3 or more, 31.4%. Of biologic users with 0 comorbidities, 21.7% used opioids; with 1 to 2 comorbidities, 32.2%; and with 3 or more, 33.3%.1
After the index date, of the systemic users, 58.8% developed 0 comorbidities, 35.4% developed 1 to 2, and 5.8% developed 3 or more. Of the biologic users, 51.3% developed 0 comorbidities, 40.2% developed 1 to 2, and 8.5% developed 3 or more. A greater number of comorbidities was associated with more PPPY outpatient visits. For systemic users with 0 comorbidities, the PPPY outpatient visit rate was 12.7; 1 to 2 comorbidities, 16.4; and 3 or more comorbidities, 24.2. For biologic users with 0 comorbidities, the PPPY outpatient visit rate was 10.4; 1 to 2 comorbidities, 14.5; and 3 or more comorbidities, 22.5.1
Before and after the index date, opioid treatment was associated with higher PPPY outpatient visit rates. For systemic users who received opioids and had 0 comorbidities, the PPPY outpatient visit rate was 14.2; 1 to 2 comorbidities, 18.8; and 3 or more comorbidities, 26.7. For biologic users who received opioids and had 0 comorbidities, the PPPY outpatient visit rate was 11.5; 1 to 2 comorbidities, 18.1; and 3 or more comorbidities, 26.4.1
Conclusions
The results of this analysis showed that patients with moderate-to-severe PsO had a high rate of opioid use, and this rate increased with the number of PsO-related comorbidities. Opioid use and/or a higher number of comorbidities was associated with a higher number of PPPY outpatient visits.1
Reference
1. Zhdanava M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefebvre P. Opioid and healthcare resource use among privately insured moderate-to-severe psoriasis patients in the US. Poster presented at: ISPOR 2019; May 18-22, 2019; New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-2217/92246.
Beyond the Surface: How New Therapies, Patient-Centered Care Are Changing Psoriasis Outcomes
August 19th 2025National Psoriasis Awareness Month offers an opportunity to examine how advances in systemic therapy, combined with patient-centered care models, are reshaping the treatment landscape.
Read More
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More